Abstract: Circulating tumor cells (CTC) have shown to be prognostic in advanced colorectal cancer (advCRC), but their value for predicting response to treatment or as a source of molecular data is debated. We compared CellSearch® (Janssen Diagnostics, LLC) and IsoFlux™ (Fluxion Biosciences Inc, South San Francisco, CA) systems for the enumeration of CTC in patients with newly diagnosed advCRC (group 1; n=34). Using castPCR™ we studied KRAS status in CTC isolated with IsoFlux™ and compared it with that of the primary tumor in patients from group 1 and in KRAS wild-type (KRAS  WT ) patients with progressive disease (group 2; n=22). Median number of CTC detected with CellSearch® (groups 1 and 2) was 1 (range: 0-78) and with IsoFlux™ (group 1) was established as the best cutoff points for predicting survival. Using castPCR™ we found KRAS mutations in CTC in 4 out of 8 patients from group 1 and in 2 out of 3 patients from group 2. None of these mutations were found in the primary tumor using standard methods, possibly reflecting intratumor heterogeneity or treatment selection pressure. We conclude that IsoFlux™ is more efficient than CellSearch® in the isolation of CTC in patients with advCRC, achieving, in a majority of cases, the established minimum of CTC for castPCR™-based genetic analyses.
Introduction
Traditional biopsies provide a static picture of a certain tumor area, which may not be the most relevant in terms of metastatic potential and resistance to treatments. Furthermore, they may be troublesome to obtain, and carry important morbidities and costs [1] , which dot not allow for their serial performance. Liquid biopsies are intended to circumvent these limitations through highly refined technologies that easily detect different biomarkers shed by tumors into the systemic circulation, such as circulating tumor cells (CTC), circulating tumor DNA (ctDNA), or exosomes among others [2, 3] .
Elevated CTC counts with the CellSearch® technology indicate a poor prognosis in breast, prostate, lung and colorectal cancers [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] . However, most CTC technologies do not recover enough number of CTC to perform molecular studies, therefore precluding CTC from becoming also a predictive tool. Indeed, the CellSearch® system, an epithelial cell adhesion molecule (EpCAM)-based immunomagnetic enrichment method, and sole FDA-approved CTC technology to date, does not allow for the recovery of CTC to perform molecular analyses [2, 14] . IsoFlux™, a novel microfluidic device that uses single or multiple capture antibodies -usually targeting EpCAM-for CTC isolation, was designed to achieve maximum recovery efficiency and cell transferability to provide sufficient CTC for molecular studies [14] . The IsoFlux system has demonstrated a high isolation effiency in locally advanced bladder cancer, and in advanced prostate, renal, CRC and non-small cell lung cancers, as well as in patients with hepatocarcinoma awaiting for a liver transplant [14] [15] [16] [17] [18] [19] . Furthermore, in bladder, prostate and renal cancers IsoFlux was able to recover enough cells for performing molecular analyses through droplet digital PCR (ddPCR) and Next Generation Sequencing (NGS) [15] [16] [17] . Liquid biopsies are expected to offer real-time data on the molecular dynamics of cancer, and this may prove specially useful in cancers with known molecular alterations with predictive and/or prognostic value [20] .
Colorectal cancer (CRC), which stands as the third most common cancer and fourth cause of mortality worldwide, is also one of the few malignancies with a predictive molecular marker (RAS status) that aids in the selection of the most appropriate treatment option [21] . any-RAS (KRAS or NRAS) mutant tumors constitute aproximately 50% of advanced CRC (advCRC) cases, 80% of which are due to mutations in KRAS [22] . all-RAS wild-type patients show an improved survival with chemotherapy plus anti-epidermal growth factor receptor (anti-EGFR) antibodies and thus benefit from more treatment options than RAS mutated patients [23] . While RAS mutational analysis and other molecular studies have been performed on ctDNA from advCRC patients, showing promise as predictive tools, few CTC technologies are claimed to efficiently recover enough cells to allow for subsequent molecular studies [24] .
Therefore, we conducted a prospective-retrospective study to test the enumeration efficiency of IsoFlux and compared it to the current standard -CellSearch®-. Finally, we tested three different Polymerase Chain Reaction (PCR)-based methods to perform KRAS mutational analysis on CTC previously recovered through IsoFlux™.
Results

a. Patient characteristics at diagnosis and at CTC collection
A total of 56 patients were included in the analysis. Thirty-four were assigned to group 1 -chemo-naïve patients-and 22 to group 2 -KRAS wild-type (KRAS  WT ) patients progressing to chemotherapy with or without anti-EGFR or antivascular endothelial growth factor (VEGF) agents. Twenty-nine were male and 27 female. Median age at diagnosis was 67 years (range: 41-84). A majority of patients had advanced disease at diagnosis (66%), with liver, lung and lymphnodes being the most common sites of metastasis (86.5%, 24% and 24%, respectively). Surgical resection of the primary had been performed in 79% of the patients. Sixteen out of 18 patients diagnosed in stages II or III had received adjuvant chemotherapy. Surgery for distant metastases had been performed in 36.5% of the patients.
At CTC collection, liver, lung and lymph-node metastases were present in 70%, 28% and 21%, respectively, and 13% had peritoneal carcinomatosis. At CTC collection 68% and 46.8% had carcinoembryonic antigen (CEA) and CA 19.9
values above their reference cut-off points (>5 ng/ml and >35 U/ml), respectively.
In group 1, 54.5% were KRAS WT and 45.5% were KRAS mutated (KRAS MUT ).
Among the 22 patients from group 2 -all KRAS WT -at the time of progression prior to CTC collection, 9 patients (41%) were receiving chemotherapy with anti-VEGF agents, 5 patients (23%) were receiving anti-EGFR agents -either combined with chemotherapy or as monotherapy-, 4 patients (18%) chemotherapy alone, and 4 patients (18%) were on treatment holidays.
Most clinico-pathological characteristics were well balanced between the two groups and are summarized in Table 2) .
In order to test the agreement between the two enumeration systems, we constructed a Bland-Altman plot, which shows that the higher the number of CTC detected with IsoFlux™ the larger the difference for CTC enumeration compared to CellSearch® (Figure 1 Table 3 . Sensitivity, specificity and Harrell's C statistic for different CTC cut-off points for CellSearch® and IsoFlux™ in patients from group 1.
The best cut-off points for each enumeration system are shown in bold. Group 1: patients chemo-naïve for advanced disease at CTC collection; CTC: circulating tumor cells. For more information, please refer to the text. . Number of CTC depending on the number of metastatic locations, and presence of pulmonary or hepatic metastases in patients from group 1 (Patients chemo-naïve for advanced disease at CTC collection). With > 3 metastatic sites vs < 3, the number of CTC detected with CellSearch® was significantly higher (3a). IsoFlux™ also detected more CTC but without reaching statistical significance (3b). There were no differences in CTC count with CellSearch® (3c) for lung metatases, but median number of CTC with IsoFlux™ was significantly higher if they were present (3d). No differences were found in CTC count with either enumeration system regarding hepatic metastases (3e, 3f). Solid lines represent the median. Four patients from group 1 and 2 patients from group 2 were found to be KRAS mutated in CTC using castPCR™. Mutations with a dCT < 21 are considered undoubtedly true mutations. In another patient from group 1, a mutation in CTC was detected but with a dCt above 21 (dCt=33) making this result inconclusive. 
Discussion
We show that IsoFlux™ is a highly efficient technology for enumerating CTC. In a cohort of chemo-naïve patients with advCRC unselected for KRAS status (group 1), IsoFlux™ detected a median of 8 CTC, while CellSearch® isolated only 1 CTC. The median number of CTC isolated with CellSearch® was significantly higher with ≥ 3 metastatic locations and showed a trend towards statistical significance with IsoFlux™.
Moreover, in the presence of lung metastases, IsoFlux™ did detect significantly more CTC than CellSearch®. Although we did not find a good correlation between the two systems, this was notably improved when there were lung metastases and when lung and hepatic metastases coexisted. Altoghether, these results suggest that both systems perform better with higher tumor burdens. We also tested the agreement between both CTC detection systems by means of a Bland-Altman plot, and show that at higher CTC counts the difference in detection eficiency with IsoFlux™ becomes wider compared to CellSearch® (Figure 1 ).
CTC ≥ 3 is established as the best cutoff for predicting survival with CellSearch® in advCRC [7, 8] , and we found a similar result in group 1 of our study (Figure 2 and Table   3 ). However, there is no established cutoff for IsoFlux™ in advCRC or in other malignancies [14] [15] [16] [17] [18] [19] . In our sample (group 1) we found ≥ 11 CTC as the best cutoff point for predicting survival with IsoFlux™, with patients below 11 CTC living significantly longer than those with ≥ 11 CTC (Figure 2) . Furthermore, Harrell's Cstatistic suggested that IsoFlux™ ≥ 11 CTC was at least as good as a predictor of survival as CellSearch® ≥ 3 CTC. However, prospective studies with a larger sample size should be conducted to confirm CTC ≥ 11 as the best prognostic cutoff for IsoFlux™ in advCRC.
We performed an exploratory analysis in patients from group 2, and found that the number of CTC detected with CellSearch did not change depending on prior treatment or not with anti-EGFR or anti-VEGF agents. The latter dissagrees with previous "in vitro" studies with a human CRC cell line, where treatment with bevacizumab increased the expression of the EpCAM 42 kDA isoform decreasing that of the constitutive 40 kDA isoform, and this correlated with a reduced CTC recovery rate with CellSearch. In our study we only used IsoFlux for CTC enumeration in three patients from group 2, very few to derive conclusions on how treatment pressure may affect the isolation efficiency with this system. This is particularly important, since anti-EpCAM capture antibodies used by CellSearch and IsoFlux may have structural differences that make the latter less susceptible to treatmentinduced changes in EpCAM isoforms expression [25] . In fact, again through spiking experiments, Bard et al [14] , showed that IsoFlux™ detected significantly more CTC than CellSearch® when EpCAM expression was low. Although no data are yet available in CRC, IsoFlux can use other capture antibodies, such as anti-EGFR antibodies, alone or in combination with anti-EpCAM antibodies, to maximize isolation efficiency [26] . To our knowledge, it is currently unknown whether the capture efficiency of these antibodies used by IsoFlux™ can be altered by anti-EGFR or anti-VEGF agents.
The median number of CTC detected with CellSearch -1 CTC-was well below the established limit of detection (LOD) for castPCR™, usually set at ≥ 4 CTC, for performing genetic analyses [14] . IsoFlux™, however, was able to isolate a median of 8 for performing genetic analyses on CTC, and a larger sample, preferably of CRC patients with high CTC counts is needed to derive conclusions ( Table 4) .
Through previous experiences -data not shown-, and concordant with other authors' reports, our laboratory established the KRAS mutation detection cutoff value (dCt KRAS) using castPCR™ at 21, such that mutations with a dCt < 21 were considered undoubtedly true mutations [14, 30] . According to this, castPCR™ detected mutations in CTC in 4 out of 8 patients from group 1 -a fifh patient was found to be mutated in CTC but with a dCt=33-, finding that KRAS had changed its status in 3 of them. In the 3 patients tested from group 2 (all KRAS WT in the primary tumor), castPCR™ detected KRAS mutations in CTC in 2 of them. Our results using castPCR™ agree with those reported by the IsoFlux manufacturer using this technology and are actually more robust, as they were performed in a larger number of only-stage IV CRC patients, while the manufacturer has only reported the results of castPCR™ on CTC in four patients with CRC in stages II and IV [14] . Not suprisingly, in all the patients where the mutation dCt in CTC was < 21, either the number of CTC (296 CTC in one patient and 203 CTC in another) or the total amount of DNA (98 ng/µl in the patient with two KRAS mutations in CTC) were especially high (see Table 5 ), suggesting, as otherwise expected, a better performance of castPCR™ in samples rich in tumoral DNA.
However, no coincidence was found between the type of mutation in the primary tumor and that in CTC. Of note, in one chemo-naïve KRAS WT patient from group 1, with a very high tumor burden and where IsoFlux™ counted 203 CTC, castPCR™ detected the mutation p.G12A [dCt 17.3], probably reflecting an underepresented subpopulation from the primary tumor not detected by TheraScreen®. In other patient from group 1 -were only 4 CTC were detected-castPCR™ found the p.G13D mutation, although with a dCt=33. In this patient primary tumor, TheraScreen® found the p.G12V mutation. A slight cross-reactivity has been described between the probes for p.G12S, p.G12D and p.G13D assays but not for the p.G12V mutation, thus making cross-reactivity an improbable explanation ( Table 5 ) [30] .
Two of the patients from group 2 found to be KRAS MUT (Table 5) . Indeed, Misale et al [31] , showed that resistance to cetuximab could either emerge from the selection of pre-existing KRAS mutant clones or as a result of new, treatment-induced mutations. Likewise, Díaz et al [32] found that metastases of CRC patients treated with the anti-EGFR panitumumab usually harbored resistant clones that expanded rapidly following treatment initiation.
The other patient from group 2 found to be KRAS MUT in CTC, had received 5 cycles of FOLFOX-Bevacizumab as first-line treatment, just before the collection of CTC at the time of progression. Interestingly, in this patient, castPCR™ unveiled two different KRAS mutations, both with a dCt below 21 (p.G12A [10.7] , p.G13D [dCt 12]) ( Table 5) .
This patient showed a very high tumor burden, with peritoneal carcinomatosis and hepatic, pulmonary and lymph-node metastases, possibly reflecting a biologically aggressive and heteregenous tumour with different cell clones, not all of them detectable by the standard KRAS mutation tests. Prior treatment with cytotoxic chemotherapy, even though it did not include an anti-EGFR agent, may also have contributed to the mutated KRAS status in CTC, in agreement with previous studies
showing that systemic therapy can enhance tumor diversity and confer a more agressive tumor phenotype [33, 34] . Likewise, prior treatment with bevacizumab in the first-line setting could have selected already existing KRAS mutant clones detectable though CTC at the time of progression. Indeed, selection of KRAS mutant clones after exposure to bevacizumab should be the object of in-depth investigations since it may have clinical implications regarding the most appropriate treatment sequence in patients with wild-type RAS advCRC [35, 36] .
These cases illustrate the advantage of "liquid" over traditional biopsies for acknowledging relevant celullar clones with potential for hematogenous dissemination and eventual metastasis. The mutational information obtained from CTC when castPCR™ is coupled to an efficient isolation system, allows to better interpret the dynamic heterogeneity of cancer and may eventually serve to take therapeutic decisions. Indeed, the intratumor heterogeneity (ITH) explains the tumor sampling bias that can occur when performing solid biopsies, as they will not inform of cell subpopulations outside the area of biopsy and, when using low-sensitivity methods for mutational analysis, small but biologically important cell subclones may go unrecognized [1] .
Our study is limited by the small sample size and the fact that CTC were collected at a single time point. Therefore we could not monitor CTC enumeration and molecular dynamics in a serial manner. It would be of interest to couple the IsoFlux system to other highly sensitive technologies like NGS, ddPCR and BEAMing (Bead Emulsion Amplification and Magnetics) -the latter claimed to have a 0.01-0.001% sensitivity-for conducting mutational studies on CTC in CRC. To our knowdledge, BEAMing has only been used in the detection of mutated ctDNA and never on CTC, and neither NGS nor ddPCR have ever been used coupled to IsoFluxin CRC [24] . Future studies should test the performance of IsoFlux combined with these technologies and, ideally, compare the performance of CTC as a predictive tool with that of ctDNA. Finally, these technologies should be used to conduct mutational analyses in solid tumor biopsies in order to unveil their genetic heterogeneity and ideally couple the results to the information provided by liquid biopsies.
Materials and methods a. Study design
This was a prospective-retrospective study, conducted in 3 hospitals in Spain. Group 1 consisted of chemo-naïve patients with advanced CRC, in which blood for CTC was extracted before starting chemotherapy.
Patients assigned to group 2 had KRAS WT advanced CRC progressing to chemotherapy for advanced disease. Blood for CTC was extracted at the time of radiologic progression prior to starting a new line of treatment. CTC enumeration was performed with both CellSearch® and IsoFlux™ in patients from group 1 and only with CellSearch® in patients from group 2. CTC recovery for KRAS mutational analysis was performed in both groups using IsoFlux™. The study was approved by the review boards of all participating institutions. All patients signed an informed consent before being enrolled in the study.
b. Patients
Patients were included between November 2013 and October 2015.
They had to be ≥ 18 years of age with histologically confirmed stage IV colorectal adenocarcinoma. Exclusion criteria included having suffered another malignancy in the previous 5 years or not fulfilling the inclusion criteria to be assigned to any of the two groups.
c. Study objectives
The 
Conclusions
IsoFlux™ is more efficient than CellSearch® in the isolation of CTC in patients with advCRC, achieving, in a majority of cases the established minimum of CTC for PCRbased genetic analyses. We propose CTC ≥ 11 as the reference cutoff point for predicting survival with IsoFlux™ in advCRC. Finally, we show that castPCR™ seems a reliable method for performing KRAS mutational studies on DNA from CTC. Together, these results indicate that CTC isolated with IsoFlux™ may be a useful prognostic marker as well as a powerful predictive tool in advCRC.
